142 related articles for article (PubMed ID: 9626113)
1. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency.
Sverrisdóttir YB; Elam M; Herlitz H; Bengtsson BA; Johannsson G
J Clin Endocrinol Metab; 1998 Jun; 83(6):1881-5. PubMed ID: 9626113
[TBL] [Abstract][Full Text] [Related]
2. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
Sverrisdóttir YB; Elam M; Caidahl K; Söderling AS; Herlitz H; Johannsson G
J Hypertens; 2003 Oct; 21(10):1905-14. PubMed ID: 14508197
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.
Elhadd TA; Abdu TA; Oxtoby J; Kennedy G; McLaren M; Neary R; Belch JJ; Clayton RN
J Clin Endocrinol Metab; 2001 Sep; 86(9):4223-32. PubMed ID: 11549653
[TBL] [Abstract][Full Text] [Related]
4. Sympathetic nerve hyperactivity is associated with increased peripheral vascular resistance in hypopituitary patients with growth hormone deficiency.
Scott EM; Greenwood JP; Stoker JB; Mary DA; Gilbey SG
Clin Endocrinol (Oxf); 2002 Jun; 56(6):759-63. PubMed ID: 12072045
[TBL] [Abstract][Full Text] [Related]
5. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism.
Krzyzanowska K; Schnack C; Mittermayer F; Kopp HP; Hofer M; Kann T; Schernthaner G
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):430-4. PubMed ID: 16151976
[TBL] [Abstract][Full Text] [Related]
7. The effects on insulin action in adult hypopituitarism of recombinant human GH therapy individually titrated for six months.
McConnell EM; Atkinson AB; Ennis C; Hadden DR; McCance DR; Sheridan B; Bell PM
J Clin Endocrinol Metab; 2001 Nov; 86(11):5342-7. PubMed ID: 11701703
[TBL] [Abstract][Full Text] [Related]
8. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
Feldt-Rasmussen U; Wilton P; Jonsson P; ;
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
[TBL] [Abstract][Full Text] [Related]
9. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.
Chrisoulidou A; Beshyah SA; Rutherford O; Spinks TJ; Mayet J; Kyd P; Anyaoku V; Haida A; Ariff B; Murphy M; Thomas E; Robinson S; Foale R; Johnston DG
J Clin Endocrinol Metab; 2000 Oct; 85(10):3762-9. PubMed ID: 11061536
[TBL] [Abstract][Full Text] [Related]
10. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome.
Tsioufis C; Dimitriadis K; Kasiakogias A; Kalos T; Liatakis I; Koutra E; Nikolopoulou L; Kordalis A; Ella RO; Lau EO; Grassi G; Papademetriou V; Tousoulis D
J Hypertens; 2017 May; 35(5):1100-1108. PubMed ID: 28106665
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory cardiovascular risk markers in women with hypopituitarism.
Sesmilo G; Miller KK; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5774-81. PubMed ID: 11739438
[TBL] [Abstract][Full Text] [Related]
12. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
Cenci MC; Conceição FL; Soares DV; Spina LD; Brasil RR; Lobo PM; Michmacher E; Vaisman M
Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.
Leimbach WN; Wallin BG; Victor RG; Aylward PE; Sundlöf G; Mark AL
Circulation; 1986 May; 73(5):913-9. PubMed ID: 3698236
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report.
Bohdanowicz-Pawlak A; Szymczak J; Bladowska J; Bednarek-Tupikowska G; Bidzińska B; Milewicz A
Med Sci Monit; 2006 Feb; 12(2):CR75-80. PubMed ID: 16449951
[TBL] [Abstract][Full Text] [Related]
16. Adults with partial growth hormone deficiency have an adverse body composition.
Murray RD; Adams JE; Shalet SM
J Clin Endocrinol Metab; 2004 Apr; 89(4):1586-91. PubMed ID: 15070916
[TBL] [Abstract][Full Text] [Related]
17. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency.
Murray RD; Shalet SM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):182-8. PubMed ID: 15670194
[TBL] [Abstract][Full Text] [Related]
18. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
19. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism.
Oertel H; Schneider HJ; Stalla GK; Holsboer F; Zihl J
Psychoneuroendocrinology; 2004 Aug; 29(7):839-50. PubMed ID: 15177699
[TBL] [Abstract][Full Text] [Related]
20. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin.
Smith JC; Lane HA; Lewis J; Dann S; Goodfellow J; Collins P; Evans LM; Scanlon MF; Davies JS
J Clin Endocrinol Metab; 2003 May; 88(5):2152-6. PubMed ID: 12727969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
